DMAC

Analyst Note: DiaMedica Therapeutics Inc. (DMAC)

Date: 2026-06-13 Current Price: $5.85

1. Structural Readiness

• Conservative Entry: — (Pending breakout confirmation)
• Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone)
• Breakout Level: — (Pending structural resolution)
• Current Price: $5.85
• Extension: —
• ATR Context: 7.7% (Very High). This indicates elevated volatility, which increases the risk of whipsaws during the formation phase but suggests significant potential for expansion if a breakout occurs.

2. Thesis Layer

• Thesis Status: TACTICAL / SETUP-LED
• Analysis: As of 2026-06-13, there is no named secular thesis attached to DMAC. The investment case is not driven by a macro theme (e.g., "AI in Healthcare" or "Aging Demographics") but is strictly a function of the technical setup quality combined with the binary nature of the clinical data catalysts. The conviction must be derived entirely from the structural integrity of the price action and the fundamental progress of the ReMEDy2 trial, rather than a broad market narrative.

3. Business Fundamentals

• Company Profile: DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS).
• Lead Asset: The primary asset is DM199 (rinvecalinase alfa), the first pharmaceutically active recombinant form of human tissue kallikrein-1 (rhKLK1) to be clinically studied. It holds Fast Track Designation from the FDA for AIS.
• Clinical Progress (ReMEDy2 Trial):
• Design: Phase 2/3, adaptive, randomized, double-blind, placebo-controlled.
• Scope: Intended to enroll approximately 300 participants at up to 100 sites globally (Evidence E10, E20).
• Interim Analysis Status: As of the May 7, 2026 earnings transcript, enrollment has surpassed 70% of the target required for the interim analysis (Evidence E2).
• Timeline: Management reiterated the intention to complete the interim analysis by the end of 2026 (Evidence E1, E9).
• Safety Data: Interim results from Part 1a (N=28 subjects) demonstrated DM199 appears safe, well-tolerated, with clinically relevant pharmacodynamic activity and no evidence of placental transfer (Evidence E15).
• Operational Challenges: Management explicitly noted "slower than expected site activations and enrollment" in the ReMEDy2 trial (Evidence E16).
• Geographic Expansion:
• Canada: Approval received in March 2026; site activation planned for the second half of 2026 (Evidence E18).
• UK: Anticipated filing of a clinical trial application in Q2 2026 (Evidence E19).
• Financial Runway: Management states that current cash and investments are sufficient to fund planned clinical studies and operations through 2027 (Evidence E6). This provides a runway extending beyond the expected interim analysis completion.
• Commercialization Timeline: Management expects the lead candidate to require significant additional testing and investment, with commercial availability not expected for at least three to four years, if at all (Evidence E13).

4. Archetype and Conviction

• Archetype: Quality Compounder (Source: layer_a).
• *Fit:* The company is executing a disciplined clinical program with a clear path to an interim readout. The "Quality" aspect is reflected in the Fast Track designation, the specific focus on high-unmet-need indications (FGR, AIS), and the management's ability to articulate a clear, albeit delayed, timeline for data delivery.
• Conviction Stack:
• Thesis Strength: Low (Tactical only; no macro tailwinds).
• Evidence Quality: High. The evidence base is robust regarding the specific trial metrics (70% enrollment, 300 target, 100 sites) and financial runway (through 2027).
• Structural Quality: Moderate. The setup is "Forming," meaning the structure is present but unconfirmed. The Very High ATR (7.7%) is a significant risk factor; historically, ATRs in the 6–8% range are elevated and correlate with higher volatility, requiring careful position sizing.
• Setup Readiness: Partial. The price is holding above the support level, but the breakout has not fired. This is a "watch" state, not a "buy" state for conservative capital.
• Rerating Potential: Binary. The rerating potential is entirely dependent on the interim analysis results in Q4 2026. If the data supports futility, the stock faces significant downside; if positive, the "Forming" coil could resolve into a "Confirmed" breakout.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• A material delay in the interim analysis timeline beyond the "end of 2026" guidance.
• Negative safety signals emerging from the ongoing Part 1a extension or new cohorts.
• What Would Strengthen:
• A confirmed breakout above the structural resistance level (pending definition).
• Acceleration of site activations in Canada or the UK.
• Confirmation that the 70% enrollment milestone is met ahead of schedule.
• Gaps in Evidence:
• Specific Financials: No specific cash balance or burn rate figures are provided in the evidence block, only the qualitative statement of sufficiency through 2027.
• Valuation Metrics: No P/S, P/B, or market cap data is available to contextualize the $5.85 price against the company's asset base.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Enrollment surpassed 70% of target for interim analysis; Cash runway sufficient through 2027; Fast Track designation for AIS; Interim analysis expected end of 2026. Key risks: Very high ATR (7.7%) indicates elevated volatility and whipsaw risk; Slower than expected site activations noted by management; Binary clinical outcome risk (futility stop); No commercial revenue for 3-4 years. Sizing hint: Position size must be reduced to account for the very high ATR and the binary nature of the upcoming data readout; do not size as a confirmed breakout. Expected path: Price likely consolidates in a forming coil structure while management executes site activations in Canada and the UK, culminating in the interim analysis data release in Q4 2026. Expected horizon: 6 to 12 months (leading up to the Q4 2026 interim analysis).